Deutsche Bank’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-24,763
| Closed | -$104K | – | 4755 |
|
|
2021
Q2 | $104K | Buy |
24,763
+6,235
| +34% | +$26.4K | ﹤0.01% | 4128 |
|
|
2021
Q1 | $92K | Sell |
18,528
-1,794
| -9% | -$14.5K | ﹤0.01% | 4021 |
|
|
2020
Q4 | $257K | Buy |
20,322
+5,767
| +40% | +$65.7K | ﹤0.01% | 3329 |
|
|
2020
Q3 | $143K | Buy |
14,555
+1,390
| +11% | +$13.7K | ﹤0.01% | 3389 |
|
|
2020
Q2 | $131K | Buy |
13,165
+3,366
| +34% | +$32.3K | ﹤0.01% | 3329 |
|
|
2020
Q1 | $87K | Buy |
9,799
+1,335
| +16% | +$13.2K | ﹤0.01% | 3313 |
|
|
2019
Q4 | $78K | Sell |
8,464
-9,429
| -53% | -$66.8K | ﹤0.01% | 3707 |
|
|
2019
Q3 | $104K | Sell |
17,893
-11,607
| -39% | -$123K | ﹤0.01% | 3528 |
|
|
2019
Q2 | $352K | Sell |
29,500
-54,517
| -65% | -$586K | ﹤0.01% | 3502 |
|
|
2019
Q1 | $1.01M | Buy |
84,017
+49,218
| +141% | +$725K | ﹤0.01% | 2982 |
|
|
2018
Q4 | $436K | Sell |
34,799
-64,098
| -65% | -$885K | ﹤0.01% | 3440 |
|
|
2018
Q3 | $1.47M | Buy |
98,897
+28,590
| +41% | +$450K | ﹤0.01% | 3048 |
|
|
2018
Q2 | $1.18M | Buy |
70,307
+39,181
| +126% | +$761K | ﹤0.01% | 3311 |
|
|
2018
Q1 | $711K | Sell |
31,126
-33,155
| -52% | -$737K | ﹤0.01% | 3509 |
|
|
2017
Q4 | $1.66M | Buy |
64,281
+43,269
| +206% | +$871K | ﹤0.01% | 2851 |
|
|
2017
Q3 | $309K | Buy |
21,012
+178
| +0.9% | +$2.58K | ﹤0.01% | 3652 |
|
|
2017
Q2 | $289K | Sell |
20,834
-35,809
| -63% | -$528K | ﹤0.01% | 3736 |
|
|
2017
Q1 | $964K | Sell |
56,643
-36,123
| -39% | -$433K | ﹤0.01% | 2675 |
|
|
2016
Q4 | $952K | Sell |
92,766
-53,538
| -37% | -$489K | ﹤0.01% | 2732 |
|
|
2016
Q3 | $1.48M | Buy |
146,304
+59,969
| +69% | +$655K | ﹤0.01% | 2553 |
|
|
2016
Q2 | $968K | Buy |
86,335
+41,165
| +91% | +$524K | ﹤0.01% | 2918 |
|
|
2016
Q1 | $614K | Buy |
45,170
+5,942
| +15% | +$85.5K | ﹤0.01% | 3096 |
|
|
2015
Q4 | $742K | Sell |
39,228
-154,922
| -80% | -$3.37M | ﹤0.01% | 3069 |
|
|
2015
Q3 | $3.64M | Buy |
194,150
+190,454
| +5,153% | +$3.24M | ﹤0.01% | 2027 |
|
|
2015
Q2 | $55K | Sell |
3,696
-184
| -5% | -$2.8K | ﹤0.01% | 4544 |
|
|
2015
Q1 | $58K | Buy |
3,880
+335
| +9% | +$4.67K | ﹤0.01% | 4343 |
|
|
2014
Q4 | $46K | Sell |
3,545
-14,720
| -81% | -$190K | ﹤0.01% | 5173 |
|
|
2014
Q3 | $230K | Sell |
18,265
-29,951
| -62% | -$290K | ﹤0.01% | 3991 |
|
|
2014
Q2 | $486K | Sell |
48,216
-25,185
| -34% | -$243K | ﹤0.01% | 3486 |
|
|
2014
Q1 | $987K | Buy |
+73,401
| New | +$1.04M | ﹤0.01% | 2866 |
|
Other funds holding CNCE
RCM
PA
ISL
Deutsche Bank's CNCE Position: Q3 2021 in Review
Deutsche Bank sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2021, closing a stake of 24,763 shares — an estimated $104K sold.
Deutsche Bank first reported a position in CNCE in Q1 2014 and held it in 30 quarters. The position peaked at $3.64M in Q3 2015. 61 funds tracked by Wall St. Rank hold CNCE as of Q3 2021.
- Deutsche Bank reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
- Deutsche Bank sold 24,763 Concert Pharmaceuticals, Inc. shares in Q3 2021, an estimated $104K.
- Deutsche Bank first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 30 quarters.
- Deutsche Bank's Concert Pharmaceuticals, Inc. position peaked at $3.64M in Q3 2015.
- 61 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2021.
Based on Deutsche Bank's 13F filing for Q3 2021, filed 4 Nov 2021.